Patents by Inventor Charles E. Chase

Charles E. Chase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11643418
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: May 9, 2023
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 11136335
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 5, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • Publication number: 20210188867
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Applicants: EISAI R&D MANAGEMENT CO., LTD., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Patent number: 10981929
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: April 20, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Hyeong-Wook Choi, Atsushi Endo, Francis G. Fang, Dae-Shik Kim
  • Patent number: 10934307
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: March 2, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 10913749
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 9, 2021
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase
  • Patent number: 10717743
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: July 21, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Publication number: 20200223864
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: March 30, 2020
    Publication date: July 16, 2020
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Patent number: 10676481
    Abstract: The invention relates to methods and intermediates useful in the synthesis of eribulin.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 9, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Phil S. Baran, Charles E. Chase, Francis G. Fang
  • Patent number: 10611773
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 7, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 10494388
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: December 3, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Publication number: 20190308992
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 10, 2019
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE
  • Publication number: 20190300542
    Abstract: The invention relates to methods and intermediates useful in the synthesis of eribulin.
    Type: Application
    Filed: February 10, 2017
    Publication date: October 3, 2019
    Inventors: Phil S. BARAN, Charles E. CHASE, Francis G. FANG
  • Publication number: 20190263826
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 29, 2019
    Inventors: Charles E. CHASE, Atsushi ENDO, Francis G. FANG, Jing LI
  • Patent number: 10308661
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Homer-Wadsworth-Emmons olefination), catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides and methods for preparing the same.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 4, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase
  • Publication number: 20190161495
    Abstract: The invention provides methods for the synthesis of a halichondrin macrolides or analogs thereof through a cyclization reaction strategy. The strategy of the present invention involves subjecting an intermediate to Prins reaction conditions to afford a macrolide. The invention also provides compounds useful as intermediates in the synthesis of a halichondrin macrolides or analogs thereof and methods for preparing the same.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 30, 2019
    Inventors: Charles E. CHASE, Hyeong-Wook CHOI, Atsushi ENDO, Francis G. FANG, Dae-Shik KIM
  • Publication number: 20190144463
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Francis G. FANG, Dae-Shik KIM, Hyeong-Wook CHOI, Charles E. CHASE, Jaemoon LEE
  • Patent number: 10221189
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: March 5, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Patent number: 10214539
    Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: February 26, 2019
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Charles E. Chase, Atsushi Endo, Francis G. Fang, Jing Li
  • Patent number: RE47797
    Abstract: Intermediates and methods of their use in the synthesis of analogs of halichondrin B are provided.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: January 7, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Farid Benayoud, Trevor Lee Calkins, Charles E. Chase, William Christ, Bryan M. Lewis, Matthew Schnaderbeck, Marc Pesant, Brian Austad, Silvio Campagna, Yongbo Hu, Gordon Wilkie, Xiaojie Zhu, Francis G. Fang